BR112013003864A2 - compostos de pirrolpirimidina e usos dos mesmos - Google Patents
compostos de pirrolpirimidina e usos dos mesmosInfo
- Publication number
- BR112013003864A2 BR112013003864A2 BR112013003864A BR112013003864A BR112013003864A2 BR 112013003864 A2 BR112013003864 A2 BR 112013003864A2 BR 112013003864 A BR112013003864 A BR 112013003864A BR 112013003864 A BR112013003864 A BR 112013003864A BR 112013003864 A2 BR112013003864 A2 BR 112013003864A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrrolpyrimidine
- compounds
- diseases
- relates
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010257786.7A CN102372717B (zh) | 2010-08-20 | 2010-08-20 | 吡咯并嘧啶类化合物及其用途 |
CN2010102577867 | 2010-08-20 | ||
CNPCTCN2010076187 | 2010-08-20 | ||
PCT/CN2010/076187 WO2012022045A1 (en) | 2010-08-20 | 2010-08-20 | Pyrrolopyrimidine compounds and uses thereof |
PCT/CN2011/078575 WO2012022265A1 (en) | 2010-08-20 | 2011-08-18 | Pyrrolopyrimidine compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013003864A2 true BR112013003864A2 (pt) | 2016-07-05 |
BR112013003864B1 BR112013003864B1 (pt) | 2021-08-31 |
Family
ID=45604781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013003864-0A BR112013003864B1 (pt) | 2010-08-20 | 2011-08-18 | Compostos de pirrolpirimidina, composição e uso dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (3) | US9346810B2 (pt) |
EP (1) | EP2606051B1 (pt) |
JP (1) | JP5749341B2 (pt) |
KR (1) | KR101541086B1 (pt) |
CN (1) | CN103119045B (pt) |
AU (1) | AU2011291185C1 (pt) |
BR (1) | BR112013003864B1 (pt) |
CA (1) | CA2808543C (pt) |
HK (1) | HK1179953A1 (pt) |
MX (1) | MX2013001970A (pt) |
NZ (1) | NZ606751A (pt) |
RU (1) | RU2563644C2 (pt) |
SG (1) | SG187742A1 (pt) |
WO (1) | WO2012022265A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
KR102196374B1 (ko) | 2012-11-29 | 2020-12-31 | 케모센트릭스, 인크. | Cxcr7 길항제 |
EP2951590A1 (en) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 |
WO2014172191A1 (en) | 2013-04-15 | 2014-10-23 | E. I. Du Pont De Nemours And Company | Fungicidal carboxamides |
TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎cyp17抑制劑/抗雄激素劑 |
WO2016197027A1 (en) * | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
CN106831779B (zh) * | 2015-11-28 | 2019-07-19 | 南昌弘益药业有限公司 | 一类jak激酶抑制剂的新化合物 |
WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
EP3458449A1 (en) | 2016-05-20 | 2019-03-27 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
SG11201901747VA (en) | 2016-08-31 | 2019-03-28 | Agios Pharmaceuticals Inc | Inhibitors of cellular metabolic processes |
CN108017641B (zh) * | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
US10414727B2 (en) * | 2016-11-08 | 2019-09-17 | Navitor Pharmaceuticals, Inc. | Phenyl amino piperidine mTORC inhibitors and uses thereof |
EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
MX2020001103A (es) | 2017-07-28 | 2020-08-17 | Nimbus Lakshmi Inc | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. |
CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
IL272667B (en) | 2017-10-18 | 2022-09-01 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
WO2019102494A1 (en) | 2017-11-24 | 2019-05-31 | Jubilant Biosys Limited | Heterocyclic compounds as prmt5 inhibitors |
CA3090842A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
CN112638879A (zh) | 2018-08-31 | 2021-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途 |
CN112638898B (zh) * | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
WO2020123582A1 (en) | 2018-12-12 | 2020-06-18 | Chemocentryx, Inc. | Cxcr7 inhibitors for the treatment of cancer |
CN110538183B (zh) * | 2019-10-09 | 2021-05-04 | 吉林大学 | 一种预防和治疗小儿湿疹的组合物及其制备方法 |
WO2022194782A1 (en) * | 2021-03-15 | 2022-09-22 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
JP7023026B1 (ja) | 2021-05-18 | 2022-02-21 | 株式会社アイビー化粧品 | Jak阻害剤 |
WO2022242768A1 (zh) * | 2021-05-21 | 2022-11-24 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的应用 |
WO2024035627A1 (en) * | 2022-08-08 | 2024-02-15 | Ajax Therapeutics, Inc. | Heterocyclic amide and urea compounds as jak2 inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
ATE423120T1 (de) | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
RS54181B9 (sr) * | 2005-12-13 | 2020-01-31 | Incyte Holdings Corp | Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
EP2530083B1 (en) * | 2006-09-22 | 2016-04-27 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
WO2008117796A1 (ja) | 2007-03-28 | 2008-10-02 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ムチリン誘導体 |
CA2682646A1 (en) * | 2007-04-02 | 2008-10-09 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
PT2473049T (pt) * | 2009-09-04 | 2019-03-04 | Sunesis Pharmaceuticals Inc | Inibidores de tirosina quinase de bruton |
US9029359B2 (en) * | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
-
2011
- 2011-08-18 WO PCT/CN2011/078575 patent/WO2012022265A1/en active Application Filing
- 2011-08-18 BR BR112013003864-0A patent/BR112013003864B1/pt not_active IP Right Cessation
- 2011-08-18 RU RU2013104520/04A patent/RU2563644C2/ru active
- 2011-08-18 AU AU2011291185A patent/AU2011291185C1/en not_active Ceased
- 2011-08-18 NZ NZ606751A patent/NZ606751A/en not_active IP Right Cessation
- 2011-08-18 US US13/817,802 patent/US9346810B2/en active Active
- 2011-08-18 SG SG2013009196A patent/SG187742A1/en unknown
- 2011-08-18 JP JP2013524343A patent/JP5749341B2/ja not_active Expired - Fee Related
- 2011-08-18 CA CA2808543A patent/CA2808543C/en not_active Expired - Fee Related
- 2011-08-18 CN CN201180040092.0A patent/CN103119045B/zh not_active Expired - Fee Related
- 2011-08-18 EP EP11817792.2A patent/EP2606051B1/en not_active Not-in-force
- 2011-08-18 KR KR1020137006853A patent/KR101541086B1/ko active IP Right Grant
- 2011-08-18 MX MX2013001970A patent/MX2013001970A/es not_active Application Discontinuation
-
2013
- 2013-06-18 HK HK13107097.2A patent/HK1179953A1/zh not_active IP Right Cessation
-
2016
- 2016-04-20 US US15/134,223 patent/US10111875B2/en not_active Expired - Fee Related
-
2018
- 2018-10-29 US US16/173,120 patent/US10369153B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20190060319A1 (en) | 2019-02-28 |
EP2606051B1 (en) | 2016-10-05 |
HK1179953A1 (zh) | 2013-10-11 |
JP2013537542A (ja) | 2013-10-03 |
JP5749341B2 (ja) | 2015-07-15 |
EP2606051A4 (en) | 2014-03-05 |
KR20130045398A (ko) | 2013-05-03 |
CA2808543C (en) | 2016-01-26 |
MX2013001970A (es) | 2013-08-09 |
AU2011291185C1 (en) | 2015-04-16 |
EP2606051A1 (en) | 2013-06-26 |
US20130210831A1 (en) | 2013-08-15 |
CA2808543A1 (en) | 2012-02-23 |
WO2012022265A1 (en) | 2012-02-23 |
US10369153B2 (en) | 2019-08-06 |
US20160228443A1 (en) | 2016-08-11 |
CN103119045B (zh) | 2016-02-17 |
AU2011291185A1 (en) | 2013-02-28 |
NZ606751A (en) | 2015-04-24 |
SG187742A1 (en) | 2013-03-28 |
US10111875B2 (en) | 2018-10-30 |
RU2563644C2 (ru) | 2015-09-20 |
KR101541086B1 (ko) | 2015-08-03 |
RU2013104520A (ru) | 2014-09-27 |
CN103119045A (zh) | 2013-05-22 |
US9346810B2 (en) | 2016-05-24 |
BR112013003864B1 (pt) | 2021-08-31 |
AU2011291185B2 (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013003864A2 (pt) | compostos de pirrolpirimidina e usos dos mesmos | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112014022000A2 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
BR112013012502A2 (pt) | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak | |
BRPI0916286B8 (pt) | amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica | |
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
BR112015002118A2 (pt) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
BR112014022106A2 (pt) | derivados macrocíclicos para o tratamento de doenças | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BRPI1015135A2 (pt) | pirimidinonas como inibidores de pi3k | |
MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
BR112013000107A2 (pt) | aminopirazoloquinazolinas | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
BR112015002152A2 (pt) | pirróis substituídos ativos como inibidores de quinases | |
BR112014030812A2 (pt) | "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr" | |
BR112014019990A8 (pt) | Compostos enediinos, seus conjugados e usos e métodos para esses compostos | |
BR112015026721A2 (pt) | derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer | |
BR112014001801A2 (pt) | indazóis | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2736 DE 13-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |